This is from Marketwatch, hence the stock angle. But the bad news for remdesivir is the same.
Dow pares some gains after reports say Gilead's remdesivir shows disappointing results
[
www.marketwatch.com]
a article on a closely followed therapeutic intended to help treat COVID-19 was reported to have shown disappointing results in a trial, according to an article by the Financial Times and Stat News. A clinical trial on the Gilead Sciences's GILD, -6.53% drug remdesivir had been viewed by the World Health Organization and accidentally published, the FT reported. The FT said that researchers studied 237 patients, giving the drug to 158 and comparing their progress with the remaining 79. The story indicated that the drug showed significant side effects in some, with 18 patients taken off it. A WHO spokesperson told Stat that the manuscript is undergoing peer review and was published by accident. Earlier this month Chinese authorities had halted two trials for remdesivir, saying that there weren't enough patients to fully enroll the studies.The Dow Jones Industrial Average DJIA, 0.37% was bouncing around in afternoon action, well of its highs, and was trading up 123 points, or 0.5%, at 23,589, the S&P 500 index SPX, 0.15% was up 0.5% at 2,812, while the Nasdaq Composite Index COMP, 0.04% was up 0.6% at 8,551. Meanwhile, shares of Gilead were down nearly 4% Thursday. A report last week from Stat News indicated that remdesivir was seeing some success but the research linked to that report was not based on a clinical study. A Gilead spokesperson was quoted as saying in Stat that reports of the research "included inappropriate characterization of the study."